medigraphic.com
ISSN 1029-3035 (Electronic)

2014, Number S1

Next >>

Mediciego 2014; 20 (S1)

Clinical, epidemiologic and therapeutic considerations on Chronic Chagas Cardiomyopathy

Morales ÁH, Pérez SLA, Jiménez CFJ, Román MO, Miranda QOM

Language: Spanish
References: 21
Page:
PDF size: 235.22 Kb.


ABSTRACT

Introduction: The Chagas Disease is a zoonosis caused by the protozoa Trypanosoma cruzi, three phases are clinically recognized: acute, indeterminate and chronic, the Chronic Chagas Cardiomyopathy is the main manifestation of the chronic phase. Objective: To know the main clinical, epidemiologic characteristics and the therapeutics of the admitted patients with Chronic Chagas Cardiomyopathy diagnosis in the Integral Diagnostic Center of Bejuma, Carabobo State, Bolivarian Republic of Venezuela. Method: An observational descriptive, cross sectional study was carried out from September 1rst, 2007 to August 31, 2009, the work universe was constituted by 395 patients older than 18 years admited in the period mentioned before, the sample was constituted by 43 patients. Results: the masculine sex was the most affected and the age group of 76 years and more was the one that prevailed in both sexes; 72.0% of patients do not remember to have got sting for the vinchuca; the peripheral edemas and exertional dyspnea were the main clinical manifestation; the more frequent electrocardiography alteration was the right Bundle-Branch Block; the inhibiting of angiotensin-converting enzyme and the loop diuretics were the most used medicines. Conclusions: Chronic Chagas Cardiomyopathy constituted 10.8% of all admited cases, most of the patients infected with Trypanosoma cruzi did not know that they were suffering this disease and those who knew it do not know the risk of sudden death for arrhythmias.


REFERENCES

  1. Kirchhoff LV. Tripanosomosis. En: Fauci AS, Kasper LD, Braunwald E, Hauser Sl, Logo DL, Jameson LJ, et al. Harrison. Principios de Medicina Interna. 17 ed. México: Mc Graw Hill; 2008. p.1300-05.

  2. Garrido F, cordova J, Rivas L, Montiel L, Luces G, Celys L, et al. Guía para el Diagnóstico, Manejo y Tratamiento de Enfermedad de Chagas en fase aguda a nivel de los Establecimientos de Salud. 1 ed. República Bolivariana de Venezuela: s.d.; 2007.

  3. Gascón J, Albajar P, Cañas E, Flores M, Prat JG, Herrera RN, et al. Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Rev Española Cardiol. 2007; 60: 285-93.

  4. Días JCP. Natural history of Chagas´ disease. Arq Bras Cardiol. 2008; 65:359-66.

  5. Basquiera AL, Capra R, Omelianiuk M, Amuchástegui M, Madoery RJ, Salomone OA. Concentraciones séricas de troponina T en pacientes con enfermedad de Chagas crónica. Rev Esp Cardiol. 2008; 56(7): 742-4.

  6. Umelisa Chagas [Internet]. La Habana: Centro de Inmunoensayo; 2007 [actualizada 8 Ene 2014; citado 8 Ene 2014]. Disponible en: http://www.tecnosuma.com/Informacion/htm/UM2014.htm

  7. Carlier Y, Luquetti AO, Días JCP, Truyens C. Chagas Disease (American Trypanosomiasis) [Internet]. Emedicine.com; 2004 [citada 10 Oct 2009] [aprox. 4 pantallas]. Disponible en: http://www.emedicine.com/med/topic327.htm

  8. Carrasco GH, Gómez C, Parada H, Guerrero L, Durán D, Molina C, Faieta A. Determinantes pronósticos en la miocardiopatía chagásica crónica. Rev Facult Med. 1992; 1(4):152-62.

  9. Zulantay I, Bozán F, Salas C, Zilleruelo N, Osuna A, Gil LC, et al. Enfermedad de Chagas crónica. Ausencia de Triatoma infestans intradomiciliario y persistencia de Trypanosoma cruzi circulante post-terapia. Parasitol Latinoam. 2008; 59:93-98.

  10. Alonso VC. Vinchucas, Trypanosomas y demás familia: nociones sobre la enfermedad de Chagas. Acta Nova. 2008; 2(3):423-31.

  11. Vidaurre T, Córdova G, Pérez L, Córdova E, Saldías J, Vivar A. Enfermedad de Chagas en sujetos asintomáticos con y sin alteraciones electrocardiográlficas en una zona endémica. Bol Soc Peruana Med Int. 1999; 12(3):125-36.

  12. Auger O, Caravello JL, Barisani G, Bustamante-Labarta H, Castagnino J, Grill I, et al. Miocardiopatía chagásica dilatada. Rev Arg Cardiol. 2007; 70(1):70-87.

  13. Storino R, Milei J. Enfermedad de Chagas. Buenos Aires: Mosby-Doyma; 1994.

  14. Roca GR, Smith V, Paz E, Lasada J, Serret B. Temas de Medicina Interna. 4 ed. La Habana: Ecimed; 2002.

  15. Keller L. El paciente con miocardiopatía chagásica crónica (I): sospecha y estudio básico. rol del electrocardiograma.Curso Intensivo sobre Enfermedad de Chagas; 2005 [Internet]. 2009 [citada 15 May 2009] [aprox. 6 pantallas]. Disponible en: http://www.fac.org.ar/ccvc/llave/c325/keller.php/

  16. Tonero O. El Paciente con Miocardiopatia Chagásica Crónica (II). Curso Intensivo sobre Enfermedad de Chagas; 2005 [Internet]. 2009 [citada 15 May 2009] [aprox. 6 pantallas]. Disponible en: http://www. www.fac.org.ar/ccvc/llave/c326/c326/

  17. Puigbó J. Contribución al estudio de la miocardiopatía chagásica crónica en Venezuela. Una visión panorámica. Parte II. Gac Med Caracas. 2001; 109(3):304-17.

  18. The Rales investigators: effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]. Am J Cardiol. 1996; 78:902-07.

  19. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with herat failure. N Engl J Med. 1997; 336(8):525-33.

  20. Packer M, O Conner C, Ghali JK. Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335:1107-14.

  21. Herrera RN, Díaz E, Pérez R, Chaín S, Sant-Yacumo R, Rodríguez E, et al. Estado protrombótico en estadios tempranos de la enfermedad de Chagas crónica. Rev Esp Cardiol. 2003; 56:377-82.




2020     |     www.medigraphic.com